Research and development of daily Sanofi CD38 antibody combination therapy reaches phase 3 clinical end

Roche Integratin Antibody UCIII Data are released at the same time; cord blood stem cell therapy omidubicel reaches the end of Phase 3 clinical trial; Fosun Pharma's pharmaceutical injection sodium fluochloroxin declaration consistency evaluation; Jianjin Pharmaceutical injection boronzomid to be included in the priority review ..We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referenceRoche is also developing a new drug, etrolizumab, with five Phase III clinical trials in UC to be released soon, two of which are compared to placebo, two with Adamu monoantigen, and one with Johnson and Johnson RemicadeThe first critical Phase III clinical data will be released in the middle of this yeartoday, Sanofi announced that its CD38 antibody, Sarclisa (isatuximab-irfc), in conjunction with dexamethasone and carfilzomib, reached the end of its main study in a mid-stage analysis of PHASE 3 clinical study IKEMA for the treatment of patients with multiple myelomaToday, Gamida Cell, a cell therapy company dedicated to finding a cure for blood cancer and severe blood diseases, announced that it is working on cell therapy, and that it is working on cell therapy to achieve positive top-of-the-line results in phase 3 clinical studies treating high-risk malignant blood cancer patients who require bone marrow transplantsToday, Moderna announced that its new coronary vaccine, mRNA-1273, has been granted fast-track status by the FDA, Fosun Pharmaceutical Holdings subsidiary Guilin South Pharmaceuticalsubmitti submitted the injection of chlorpyrifos sodium consistency evaluation supplement application was accepted by CDE, the acceptance number is CYHB2050235, CYHB2050236, CYHB205023712, East Sunshine Drug Class 1 new drug HEC89736PTSA0.5H2O tablet clinical application was accepted by CDE, accepted by CXHL2000195, CXHL2000196, CXHL200019712, CDE official website shows that Jianjin Pharmaceutical's injection of boronzomi is to be included in the priority review, included in the reason sedative "same production line production, has been listed in the United States in 2020, apply for domestic listing."days ago, Invivoscribe announced that the company had submitted to Chinese regulators in April a LeukoStratCDxFLT3 mutation test application to support Astellas Pharmaceuticals' application for xoSPATAnew drug for the treatment of adult patients with FLT3 mutation severation or difficulty with treating acute myeloid leukemiaToday, Consino Bio announced that the company is working with the National Research Council of Canada to advance clinical trials of the recombinant public health event vaccine in CanadaThis clinical study begins with Phase I/II and is aimed at conducting Phase III to demonstrate the clinical protection effectiveness of the vaccine as quickly as possibleHydroxychloroquine did not reduce the risk of death or needing a ventilator in nearly 1,400 patients treated at Columbia University in New York, the researchers reported recently in new England Journal of Medicine.